Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-19T02:24:31.040Z Has data issue: false hasContentIssue false
  • English
  • Français

Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series

Published online by Cambridge University Press:  16 April 2020

B. Croissant ,
O. Klein ,
L. Gehrlein ,
A. Kniest ,
D. Hermann ,
A. Diehl  and
K. Mann
B. Croissant*
Affiliation:
Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, J 5, D-68159Mannheim, Germany
O. Klein
Affiliation:
Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, J 5, D-68159Mannheim, Germany
L. Gehrlein
Affiliation:
Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, J 5, D-68159Mannheim, Germany
A. Kniest
Affiliation:
Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, J 5, D-68159Mannheim, Germany
D. Hermann
Affiliation:
Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, J 5, D-68159Mannheim, Germany
A. Diehl
Affiliation:
Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, J 5, D-68159Mannheim, Germany
K. Mann
Affiliation:
Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, J 5, D-68159Mannheim, Germany
*
*Corresponding author. E-mail address: [email protected] (B. Croissant).
Get access

Abstract

Purpose

Quetiapine is a novel antipsychotic, which is efficacious in the treatment of positive and negative symptoms in schizophrenia. Research has shown that atypical antipsychotic also reduce the craving and consumption for stimulants and alcohol. Due to Quetiapine's particulars and the promising receptor profile concerning addiction medicine, we set out to examine the tolerability and efficacy concerning relapse prevention of withdrawn alcoholics suffering from craving and affective symptoms.

Subjects and methods

Our case observations attempted to evaluate nine alcoholics after withdrawal suffering from persisting craving, sleep disorder, excitement, depressive symptoms or anxiety symptoms. The patients were treated with quetiapine as relapse prevention and we followed them up in our outpatient clinic.

Results

Eight out of nine patients were abstinent under quetiapine over a period of 2–7 months. One of these patients relapsed after he stopped taking the preparation at his own initiative after 10 weeks. The ninth patient stopped taking the preparation immediately because of swollen nasal mucosae. All target symptoms disappeared in the patients after an average of (mean ± S.D.) 24.5 ± 18.1 days. The overall tolerability was considered to be very good; however, initial sleepiness appeared in four patients.

Conclusion

Although uncontrolled case observations can only be interpreted with caution quetiapine seems to deserve further investigation and may hold the potential for preventing alcohol relapse in alcoholics suffering from additional above-mentioned symptoms.

Keywords

QuetiapineAlcohol relapse preventionCravingSleep disorderAffective symptomsExcitement
Type
Case report
Information
European Psychiatry , Volume 21 , Issue 8 , December 2006 , pp. 570 - 573
Copyright
Copyright © Elsevier Masson SAS 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Breier, A., Buchanan, R.W., Waltrip, R.W. 2nd Listwak, S., Holmes, C., Goldstein, D.S.The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy Neuropsychopharmacology 10(1)1994 1–7.CrossRefGoogle ScholarPubMed
Brown, E.S., Nejtek, V.A., Perantie, D.C., Bobadilla, L.Quetiapine in bipolar disorder and cocaine dependence Bipolar Disord. 4(6)2002 406–411.CrossRefGoogle ScholarPubMed
Brown, S.A., Schuckit, M.A.Changes in depression among abstinent alcoholics J. Stud. Alcohol 49(5)1988 412–417.CrossRefGoogle ScholarPubMed
Gimenez-Roldan, S., Navarro, E., Mateo, D.Effects of quetiapine at low doses on psychosis motor disability and stress of the caregiver in patients with Parkinson’s disease Rev. Neurol. 36(5)2003 401–404.Google ScholarPubMed
Goldstein, J.Quetiapine fumarate (Seroquel): a new atypical antipsychotic Drugs Today 1999; 35:193–210.CrossRefGoogle ScholarPubMed
Heinz, A., Mann, K., Weinberger, D.R., Goldman, D.Serotonergic dysfunction, negative mood states, and response to alcohol Alcohol. Clin. Exp. Res. 25(4)2001 487–495.CrossRefGoogle ScholarPubMed
Hutchison, K.E., Swift, R., Rohsenow, D.J., Monti, P.M., Davidson, D., Almeida, A.Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol Psychopharmacology (Berl.) 155(1)2001 27–34.CrossRefGoogle Scholar
Johnson, B.A.Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment CNS Drugs 18(15)2004 1105–1118.CrossRefGoogle ScholarPubMed
Johnson, B.A., Jasinski, D.R., Galloway, G.P., Kranzler, H., Weinreib, R., Anton, R.F.et al.Ritanserin in the treatment of alcohol dependence––a multicenter clinical trial. Ritanserin Study Group Psychopharmacology (Berl.) 128(2)1996 206–215.CrossRefGoogle ScholarPubMed
Johnson, B.A., Roache, J.D., Javors, M.A., DiClemente, C.C., Cloninger, C.R., Prihoda, T.J.et al.Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial JAMA 284(8)2000 963–971.CrossRefGoogle ScholarPubMed
Litten, R.Z., Allen, J., Fertig, J.Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991 Alcohol. Clin. Exp. Res. 20(5)1996 859–876.CrossRefGoogle ScholarPubMed
Malcolm, R., Myrick, H., Roberts, J., Wang, W., Anton, R.F.The differential effects of medication on mood, sleep disturbance, and work ability in outpatient alcohol detoxification Am. J. Addict. 11(2)2002 141–150.CrossRefGoogle ScholarPubMed
Mann, K.Pharmacotherapy of Alcohol Dependence: a review of the clinical data CNS Drugs 18(8)2004 485–504.CrossRefGoogle ScholarPubMed
Marra, D., Warot, D., Berlin, I., Hispard, E., Notides, C., Tilikete, S.et al.Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial Alcohol. Clin. Exp. Res. 26(10)2002 1545–1552.CrossRefGoogle Scholar
McBride, W.J., Lovinger, D.M., Machu, T., Thielen, R.J., Rodd, Z.A., Murphy, J.M.et al.Serotonin-3 receptors in the actions of alcohol, alcohol reinforcement, and alcoholism Alcohol. Clin. Exp. Res. 28(2)2004 257–267.CrossRefGoogle ScholarPubMed
Meert, T.F., Awouters, F., Niemegeers, C.J., Schellekens, K.H., Janssen, P.A.Ritanserin reduces abuse of alcohol, cocaine, and fentanyl in rats Pharmacopsychiatry 24(5)1991 159–163.CrossRefGoogle ScholarPubMed
Mitchell, P.B., Malhi, G.S.Treatment of bipolar depression: focus on pharmacologic therapies Expert Rev. Neurother. 5(1)2005 69–78.CrossRefGoogle ScholarPubMed
Modell, J.G., Mountz, J.M., Glaser, F.B., Lee, J.Y.Effect of haloperidol on measures of craving and impaired control in alcoholic subjects Alcohol. Clin. Exp. Res. 17(2)1993 234–240.CrossRefGoogle ScholarPubMed
Monti, P.M., Rohsenow, D.J., Hutchison, K.E., Swift, R.M., Mueller, T.I., Colby, S.M.et al.Naltrexone’s effect on cue-elicited craving among alcoholics in treatment Alcohol. Clin. Exp. Res. 23(8)1999 1386–1394.Google ScholarPubMed
Potvin, S., Stip, E., Roy, J.Y.Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses Int. Clin. Psychopharmacol. 18(3)2003 121–132.Google ScholarPubMed
Regier, D.A., Farmer, M.E., Rae, D.S., Locke, B.Z., Keith, S.J., Judd, L.L.et al.Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study JAMA 264(19)1990 2511–2518.CrossRefGoogle ScholarPubMed
Sajatovic, M., Mullen, J.A., Sweitzer, D.E.Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis J. Clin. Psychiatry 63(12)2002 1156–1163.CrossRefGoogle ScholarPubMed
Sajatovic, M.Treatment for mood and anxiety disorders: quetiapine and aripiprazole Curr. Psychiatry Rep. 5(4)2003 320–326.CrossRefGoogle ScholarPubMed
Schuckit, M.A., Tipp, J.E., Bergman, M., Reich, W., Hesselbrock, V.M., Smith, T.L.Comparison of induced and independent major depressive disorders in 2,945 alcoholics Am. J. Psychiatry 154(7)1997 948–957.Google ScholarPubMed
Weissman, M.M., Myers, J.K., Harding, P.S.Prevalence and psychiatric heterogeneity of alcoholism in a United States urban community J. Stud. Alcohol 41(7)1980 672–681.CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.